文献速递冠心病血脂与心血管预防

冠状动脉CT血管造影与血流储备分数指导稳定性缺血性心脏病患者管理

Coronary CT Angiographic and Flow Reserve-Guided Management of Patients With Stable Ischemic Heart Disease.
PubMed 文献 · J Am Coll Cardiol · 2018-08-25

本研究回顾了3674例稳定性胸痛患者,采用冠状动脉CT血管造影(CTA)及选择性FFRCT指导中间狭窄(30%-70%)患者的下游管理。中位随访24个月,复合终点在CTA狭窄<30%组与FFRCT>0.80组间无显著差异,而FFRCT≤0.80组事件率更高;FFRCT≤0.80且转诊有创冠状动脉造影组心肌梗死风险低于未转诊组。结论提示FFRCT有助于区分无需进一步检查或干预的低风险患者与可能需要有创评估的高风险患者。

要点

  • FFRCT>0.80且仅优化药物治疗的患者复合终点发生率与CTA狭窄<30%者相当。
  • FFRCT≤0.80未转诊有创检查者复合终点发生率显著高于CTA狭窄<30%组。
  • FFRCT≤0.80转诊有创冠状动脉造影者心肌梗死风险低于未转诊者。

核心结论

  • 在中间范围冠状动脉狭窄患者中,FFRCT能有效区分无需进一步诊断检查或干预的低风险患者(FFRCT>0.80)与可能需要有创冠状动脉造影及干预的高风险患者(FFRCT≤0.80)。

研究设计与样本

  • 回顾性研究,纳入3674例连续性稳定性胸痛患者,均接受CTA及选择性FFRCT检查以指导中间狭窄(30%至70%)患者的下游管理,中位随访24个月(范围8至41个月)。

主要发现

  • 677例患者获得FFRCT结果,其中410例(61%)FFRCT>0.80。
  • FFRCT>0.80的患者中75%最大冠状动脉狭窄≥50%。
  • 复合终点累积发生率:组1(CTA狭窄<30%,优化药物治疗,无额外检查)为2.8%(95%CI:1.4%至4.9%),组2(FFRCT>0.80,优化药物治疗,无额外检查)为3.9%(95%CI:2.0%至6.9%),两组比较p=0.58。
  • 与组1相比,组3(FFRCT≤0.80,优化药物治疗,无额外检查)复合终点发生率为9.4%(p=0.04),组4(FFRCT≤0.80,优化药物治疗,转诊有创冠状动脉造影)为6.6%(p=0.08)。
  • 心肌梗死风险组4(1.3%)低于组3(8%),p<0.001。

临床怎么用

  • 对于稳定性胸痛且CTA显示中间狭窄(30%至70%)的患者,可考虑行FFRCT以辅助决策。
  • FFRCT>0.80者可仅接受优化药物治疗而暂不进一步检查或干预。
  • FFRCT≤0.80者可能需要转诊有创冠状动脉造影并考虑干预。

局限性

  • 研究为回顾性设计,FFRCT仅在部分患者(677例)中可用,可能存在选择偏倚。
  • 作者指出需要进一步研究评估一线CTA联合选择性FFRCT检查患者的风险及最佳管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical outcomes following coronary computed tomography-derived fractional flow reserve (FFRCT) testing in clinical practice are unknown. OBJECTIVES: This study sought to assess real-world clinical outcomes following a diagnostic strategy including first-line coronary computed tomography angiography (CTA) with selective FFRCT testing. METHODS: The study reviewed the results of 3,674 consecutive patients with stable chest pain evaluated with CTA and FFRCT testing to guide downstream management in patients with intermediate stenosis (30% to 70%). The composite endpoint (all-cause death, myocardial infarction, hospitalization for unstable angina, and unplanned revascularization) was determined in 4 patient groups: 1) CTA stenosis <30%, optimal medical treatment (OMT), and no additional testing; 2) FFRCT >0.80, OMT, no additional testing; 3) FFRCT ≤0.80, OMT, no additional testing; and 4) FFRCT ≤0.80, OMT, and referral to invasive coronary angiography. Patients were followed for a median of 24 (range 8 to 41) months. RESULTS: FFRCT was available in 677 patients, and the test result was negative (>0.80) in 410 (61%) patients. In 75% of the patients with FFRCT >0.80, maximum coronary stenosis was ≥50%. The cumulative incidence proportion (95% confidence interval [CI]) of the composite endpoint at the end of follow-up was comparable in groups 1 (2.8%; 95% CI: 1.4% to 4.9%) and 2 (3.9%; 95% CI: 2.0% to 6.9%) (p = 0.58) but was higher (when compared with group 1) in groups 3 (9.4%; p = 0.04) and 4 (6.6%; p = 0.08). Risk of myocardial infarction was lower in group 4 (1.3%) than in group 3 (8%; p < 0.001). CONCLUSIONS: In patients with intermediate-range coronary stenosis, FFRCT is effective in differentiating patients who do not require further diagnostic testing or intervention (FFRCT >0.80) from higher-risk patients (FFRCT ≤0.80) in whom further testing with invasive coronary angiography and possibly intervention may be needed. Further studies assessing the risk and optimal management strategy in patients undergoing first-line CTA with selective FFRCT testing are needed.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nørgaard BL, Terkelsen CJ, Mathiassen ON, et al. Coronary CT Angiographic and Flow Reserve-Guided Management of Patients With Stable Ischemic Heart Disease. J Am Coll Cardiol. 2018. PMID: 30153968. doi:10.1016/j.jacc.2018.07.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。